Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Technosphere Insulin using the Gen2C inhaler · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Regular Human Insulin | ACTIVE_COMPARATOR | Subcutaneous injection |
| TI and Regular Human Insulin | EXPERIMENTAL | All subjects have 4 clamp procedures with 10, 30, 60,80 units of TI and 1 clamp with 15 IU Regular Human Insulin |
| Name | Type | Description |
|---|---|---|
| Technosphere Insulin Inhalation Powder using the Gen2C inhaler | DRUG | Inhalation Powder |
| Regular Human Insulin | DRUG | Subcutaneous injection |
Inclusion Criteria: * Men and women aged 18 to 55 years who are considered healthy based on screening physical examination, medical history, clinical chemistry, and urinalysis * Good venous access for blood draws * No smoking in the previous 6 months (including cigarettes, cigars, pipes) and negati...
Technosphere Insulin using the Gen2C inhaler is an inhaled formulation of insulin delivered as a powder through the Gen2C inhaler device. It is being developed by MannKind Corporation and has been studied in a Phase 1 clinical trial in healthy volunteers.
Technosphere Insulin using the Gen2C inhaler is developed by MannKind Corporation, which trades under the ticker MNKD. MannKind is the company responsible for the Technosphere inhalation technology platform.
Technosphere Insulin using the Gen2C inhaler is in Phase 1 clinical development. It is investigational and has not been approved by the FDA. The Phase 1 trial has been completed.
Technosphere Insulin using the Gen2C inhaler has been evaluated in one completed Phase 1 trial, NCT01490762, titled "Healthy Normal Volunteers Looking at Exposure and Effects of Multiple Doses of Technosphere Insulin (TI) Using the Gen2C Inhaler." The trial enrolled 35 healthy volunteers in the United States.